Who Paid My Doc
A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate
Research payments
$9,221,490
Through program year 2025, $9,221,490 in research payments was reported against A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate, across 984 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $128,336 | 43 |
| 2024 | Research | $685,019 | 53 |
| 2023 | Research | $695,758 | 161 |
| 2022 | Research | $5,869,133 | 530 |
| 2021 | Research | $1,843,245 | 197 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Louis Saravolatz Grosse Pointe Woods, MI Named on 34 payments
- Alejandro Hoberman Pittsburgh, PA Named on 31 payments
- Alexander White Port Orange, FL Named on 20 payments
- Adebayo Akinsola Chamblee, GA Named on 20 payments
- Divya Batra Quincy, IL Named on 19 payments
- Robert Bell Beaumont, TX Named on 18 payments
- Wayne Harper Raleigh, NC Named on 17 payments
- Darvy Mann Longview, TX Named on 16 payments
- Marian Shaw Boise, ID Named on 16 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.